67 results
8-K
VIR
Vir Biotechnology Inc
5 Jun 24
Regulation FD Disclosure
6:04am
with chronic hepatitis delta. The Company reiterated in the press release a June 5, 2024, investor conference call at 6:00 a.m. Eastern Time / 12:00 p.m … calls, the Company’s plans and expectations for its chronic hepatitis delta and chronic hepatitis B programs, and risks and uncertainties associated
8-K
EX-99.1
VIR
Vir Biotechnology Inc
5 Jun 24
Regulation FD Disclosure
6:04am
, for the treatment of people living with chronic hepatitis delta. Preliminary data from the Phase 2 trial show treatment with tobevibart alone … elevations in LFTs were observed.
“As the most severe form of viral hepatitis, chronic hepatitis delta poses a significant threat to millions worldwide
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
of tobevibart and elebsiran; the ability of tobevibart and elebsiran (as monotherapies or combination therapies) to treat and/or prevent chronic … hepatitis Delta (CHD) or chronic hepatitis B virus (CHB); the Company’s preclinical pipeline; the Company’s collaboration with the Biomedical Advanced
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
a corporate update and reported financial results for the first quarter ended March 31, 2024.
“We are excited to share important data from our Phase 2 chronic … for the company.”
Pipeline Programs
Chronic Hepatitis Delta (CHD)
On March 5, 2024, Vir announced its Phase 2 chronic hepatitis delta SOLSTICE trial completed
8-K
EX-99.1
xzd1c u34bctpq
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
pd6trpan
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
8-K
EX-99.1
pkbhv2nir6b
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
EX-99.1
ea0ar4e4b4yz
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
nwj3lsuhtjg8 nw83ix
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
8-K
EX-99.1
o1pd 3b8k0pdgezib
3 Nov 22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
2yxky4p8
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am